BGD — Biogened SA Income Statement
0.000.00%
- PLN66.32m
- PLN82.12m
- PLN110.93m
- 85
- 61
- 49
- 76
Annual income statement for Biogened SA, fiscal year end - December 31st, PLN millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | PAS | PAS | PAS | PAS | PAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 48.3 | 65.3 | 79.6 | 95.6 | 111 |
Cost of Revenue | |||||
Gross Profit | 33 | 42.3 | 57.4 | 63.5 | 76.7 |
Selling / General / Administrative Expenses | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 45.5 | 61.5 | 71.2 | 86.5 | 102 |
Operating Profit | 2.87 | 3.87 | 8.41 | 9.04 | 9.38 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 2.06 | 3.61 | 6.39 | 6.89 | 6.84 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1.13 | 1.24 | 3.38 | 5.1 | 4.97 |
Net Income Before Extraordinary Items | |||||
Net Income | 1.13 | 1.24 | 3.38 | 5.1 | 4.97 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1.24 | 1.96 | 3.38 | 5.1 | 5.82 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.367 | 0.798 | 1.37 | 1.81 | 2.28 |
Dividends per Share |